open access

Vol 14, No 3 (2018)
Other materials agreed with the Editors
Published online: 2018-03-13
Get Citation

Maciej Kawecki1
DOI: 10.5603/OCP.2018.0023
·
Oncol Clin Pract 2018;14(3):167-170.


Affiliations

  1. Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Institute of Oncology, Warsaw

open access

Vol 14, No 3 (2018)
CURRENT LITERATURE REVIEW
Published online: 2018-03-13

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 3 (2018)

Article type

Other materials agreed with the Editors

Pages

167-170

Published online

2018-03-13

DOI

10.5603/OCP.2018.0023

Bibliographic record

Oncol Clin Pract 2018;14(3):167-170.

Authors

Maciej Kawecki

References (8)
  1. Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20): 1919–1929.
  2. Petrylak DP, de Wit R, Chi KN, et al. RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017; 390(10109): 2266–2277.
  3. Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11): 1015–1026.
  4. Mok TS, Wu YL, Ahn MJ, et al. AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017; 376(7): 629–640.
  5. Mok TSK, Kim SW, Wu YL, et al. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017; 35(36): 4027–4034.
  6. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015; 16(8): 990–998.
  7. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018: Lancet.
  8. Chow PKH, Gandhi M, Tan SB, et al. Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018 [Epub ahead of print]: JCO2017760892.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl